» Articles » PMID: 39062497

Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Jul 27
PMID 39062497
Authors
Affiliations
Soon will be listed here.
Abstract

Tetracyclines constitute a unique class of antibiotic agents, widely prescribed for both community and hospital infections due to their broad spectrum of activity. Acting by disrupting protein synthesis through tight binding to the 30S ribosomal subunit, their interference is typically reversible, rendering them bacteriostatic in action. Resistance to tetracyclines has primarily been associated with changes in pump efflux or ribosomal protection mechanisms. To address this challenge, tetracycline molecules have been chemically modified, resulting in the development of third-generation tetracyclines. These novel tetracyclines offer significant advantages in treating infections, whether used alone or in combination therapies, especially in hospital settings. Beyond their conventional antimicrobial properties, research has highlighted their potential non-antibiotic properties, including their impact on immunomodulation and malignancy. This review will focus on third-generation tetracyclines, namely tigecycline, eravacycline, and omadacycline. We will delve into their mechanisms of action and resistance, while also evaluating their pros and cons over time. Additionally, we will explore their therapeutic potential, analyzing their primary indications of prescription, potential future uses, and non-antibiotic features. This review aims to provide valuable insights into the clinical applications of third-generation tetracyclines, thereby enhancing understanding and guiding optimal clinical use.

Citing Articles

Design and Application of an Imprinted Polymer Sensor for the Dual Detection of Antibiotic Contaminants in Aqueous Samples and Food Matrices.

Jamieson O, Bell J, Hudson A, Saczek J, Perez-Padilla V, Kaiya G ACS Appl Polym Mater. 2025; 7(4):2265-2273.

PMID: 40046615 PMC: 11877416. DOI: 10.1021/acsapm.4c03218.


(Bio)Electroanalysis of Tetracyclines: Recent Developments.

Madej M, Knihnicki P, Porada R, Kochana J Biosensors (Basel). 2025; 15(2).

PMID: 39997003 PMC: 11853472. DOI: 10.3390/bios15020101.


Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.

Karamanolis N, Kounatidis D, Vallianou N, Dimitriou K, Tsaroucha E, Tsioulos G Antibiotics (Basel). 2025; 14(1).

PMID: 39858295 PMC: 11762948. DOI: 10.3390/antibiotics14010009.

References
1.
Abbey T, Vialichka A, Jurkovic M, Biagi M, Wenzler E . Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility. Microbiol Spectr. 2022; 10(3):e0054222. PMC: 9241703. DOI: 10.1128/spectrum.00542-22. View

2.
Solomkin J, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D . IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. Clin Infect Dis. 2018; 69(6):921-929. PMC: 6735687. DOI: 10.1093/cid/ciy1029. View

3.
Yang F, Chen P, Wang H, Xing X, Wang S, Ishaq H . Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against . Microb Drug Resist. 2021; 28(2):229-235. DOI: 10.1089/mdr.2021.0228. View

4.
Heidrich C, Mitova S, Schedlbauer A, Connell S, Fucini P, Steenbergen J . The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome. Antibiotics (Basel). 2016; 5(4). PMC: 5187513. DOI: 10.3390/antibiotics5040032. View

5.
Dong N, Zeng Y, Wang Y, Liu C, Lu J, Cai C . Distribution and spread of the mobilised RND efflux pump gene cluster tmexCD-toprJ in clinical Gram-negative bacteria: a molecular epidemiological study. Lancet Microbe. 2022; 3(11):e846-e856. DOI: 10.1016/S2666-5247(22)00221-X. View